In this PiPCast®, Naomi Pearce walks through the key IP strategies biosimilars companies are using to enable market entry globally, and canvas biosimilar litigation in Australian courts. They also discuss recent litigation settlement activity and lessons learnt.
Significant biosimilar activities this week include: 25 Aug 22 | JP | Lupin and I’rom sign licence for denosumab in Japan Lupin announced that it has entered into an exclusive...
Significant biosimilar activities this week include: 12 Aug 22 | US | Alvotech, Mylan & others file amicus curiae briefs in support of Teva’s skinny label case Alvotech,...
In this PiPCast™, we discuss whether a patent inventor must be human or can include artificial intelligence systems in Australia, and look to the future legal developments in this space.
Significant biosimilar activities this week include: 23 Aug 22 | Amgen announces the results of Ph III eculizumab trials Amgen announced the results of a Ph III study evaluating...
Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2022] HCA 29Date:Court:Judges:17 June 2022High Court of AustraliaKiefel CJ, Gageler, Keane, Gordon, Edelman...
Even the High Court of Australia could not come to a majority decision on the thorny question of the patentability of computer-implemented inventions in its highly anticipated...
Significant biosimilar activities this week include: 11 Aug 22 | ALX Oncology initiates Ph II trials of evorpacept in combination with cetuximab and pembrolizumab ALX Oncology...
Significant biosimilar activities this week include: 27 Jul 22 | CN | Ph III trial shows Qila’s denosumab biosimilar improves bone mineral density It has been reported that a Ph...
Significant biosimilar activities this week include: 27 Jul 22 | AU | Viatris (Mylan) seeks PBS listing for etanercept biosimilar Alphapharm (Viatris’ Australian subsidiary) has...
In the field of medicinal cannabis, plant varietal or cultivar names that are protected by a registered right such as a PBR (plant breeder right) are often mirrored in commercial...
Pearce IP’s Naomi Pearce speaks about the hot topic in Australian patent law: Patent Term Extension (PTE) in Australia
Chimeric Antigen Receptor (CAR)-T cell therapy is a pioneering technology that is successfully changing the way we think about the treatment of cancer, in particular blood...
Introduction Plant based protein products are already a well established destination in the supermarket aisle. Australia is reportedly the third fastest growing market for such...
Significant biosimilar activities this week include: 25 Jul 22 | US | FDA accepts ABLA for natalizumab biosimilar Sandoz announced that the FDA has accepted its ABLA for a...
We are proud to announce that Pearce IP and its CEO have been shortlisted for three awards at the APAC 2022 Women in Business Law Awards, with the winners to be announced on...
With great pleasure, we announce that our CEO and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been named as one of the Australasian Lawyer’s Most...
The Full Court’s decision in Boehringer Ingelheim Animal Health USA Inc., v Intervet International B.V. [2022] FCAFC 88 is a useful analysis of the application of the “Cripps...
18 Jul 22 | MENA | Hikma and Celltrion enter into commercialisation agreement for YuflymaTM Hikma Pharmaceuticals announced that it has entered into a commercialisation agreement...
Globaltech Corporation Pty Ltd v Reflex Instruments Asia Pacific Pty Ltd [2022] FCA 797Date:Court:Judge:12 July 2022Federal Court of AustraliaJagot JBackground Globaltech...
11 Jul 22 | Overland ADCT commences trials of Zynlonta® in combination with rituximab in DLBCL Overland ADCT BioPharma announced the dosing of the first patient in China in its...
The key terms of an updated draft covid IP waiver have been released by the WTO. The draft includes terms intended to alleviate concerns of developed countries. However it will...
This week Pearce IP celebrated its 5th birthday, and received glowing reviews and rankings for the firm, and for three of its individual patent professionals by IAM Patent 1000....
04 Jul 22 | US | Xbrane Biopharma provides update on ranibizumab biosimilar Xbrane Biopharma confirmed that it will resubmit a BLA for its biosimilar to Lucentis® (ranibizumab)...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
